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mucosal injury and modulates intestinal epithelial
restitution following acetic acid induced intestinal
injury in rats
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Beneficial effects of glutamine (GLN) have been described in many gastrointestinal disorders. The aim of the
present study was to evaluate the preventative effect of oral GLN supplementation against acetic acid (AA) induced
intestinal injury in a rat. Male Sprague–Dawley rats were divided into four experimental groups: control (CONTR)
rats underwent laparotomy, control-glutamine (CONTR-GLN) rats were treated with enteral glutamine given in
drinking water (2%) 48 hours before and five days following laparotomy, AA rats underwent laparotomy and
injection of AA into an isolated jejunal loop, and acetic acid-glutamine (AA-GLN) rats underwent AA-induced injury
and were treated with enteral GLN 48 hours before and 5 days following laparotomy. Intestinal mucosal damage
(Park’s injury score), mucosal structural changes, enterocyte proliferation and enterocyte apoptosis were determined
five days following intestinal injury. Western blotting was used to determine p-ERK and bax protein levels. AA-induced
intestinal injury resulted in a significantly increased intestinal injury score with concomitant inhibition of cell turnover
(reduced proliferation and enhanced apoptosis). Treatment with dietary GLN supplementation resulted in a decreased
intestinal injury score with concomitant stimulation of cell turnover (enhanced proliferation and reduced
apoptosis). In conclusion, pre-treatment with oral GLN prevents mucosal injury and improves intestinal recovery
following AA-induced intestinal injury in rats.
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InflammationIntroduction
The identification of factors that prevent mucosal injury
during intestinal damage as well as factors that improve
intestinal restitution following intestinal injury may reveal
new therapeutic strategies for maintaining mucosal integ-
rity of the gastrointestinal (GI) tract, thus improving out-
comes in patients with intestinal inflammation. Intracolonic
administration of acetic acid (AA) has been previously
described as a model of experimental colitis [1]. We* Correspondence: igor-dr@internet-zahav.net
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reproduction in any medium, provided the orrecently developed a novel rodent model system to study
AA-induced small intestinal injury, whereby acetic acid
(0.67 mol/L) was directly administered to a ligated intes-
tinal loop in anesthetized rats, leading to histological
injury and alterations in intestinal permeability [2]. AA
treatment induced major histopathological changes in the
intestinal mucosa, including small, irregular, and distorted
villi; epithelial damage; edema of the lamina propria; in-
flammatory cell accumulation; and hemorrhage. This new
model was utilized to study the role of glutamine (GLN)
in AA-induced small bowel injury, which is becoming an
increasingly relevant topic since this form of GI injury is
quite common among patients with Crohn’s disease.
GLN is a non-essential amino acid, produced mainly by
muscle, and plays an important role in many physiologicaltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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GLN is an important nutrient for rapidly dividing cells
such as those found in the immune system and gut [3].
Extensive studies involving various experimental models
have established that GLN is an essential respiratory
substrate for cells in the small intestinal mucosa, ac-
counting for over one third of the total CO2 produced
in the small intestine [4]. In addition, GLN exerts a
positive effect on gut-associated lymphoid tissue and
enhances gut barrier function.
Given the trophic gut effects of GLN, we hypothesized
in the present study that this amino acid could prevent
intestinal mucosal injury and/or improve intestinal recov-
ery following AA-induced intestinal damage. GLN might
stimulate enterocyte turnover via direct stimulation of
proliferation or cell migration, or by inhibition of entero-
cyte apoptosis. Previous studies have shown that intestinal
damage results in the appearance of apoptotic and nec-
rotic cells in intestinal epithelium. Furthermore, stimula-
tion of apoptosis is more pronounced in epithelial cells
within the upper portions of the villi when compared to
the undifferentiated proliferating cells in the crypts of
Lieberkühn [5].
The purpose of the present study was to evaluate the
effect of dietary GLN supplementation on structural
mucosal changes following AA-induced intestinal injury
in a rat model and to evaluate the mechanisms by which
glutamine influences intestinal recovery, including its ef-
fect on enterocyte proliferation and death via apoptosis.
Materials and methods
Animals
Male Sprague–Dawley rats weighing 250-350 g were han-
dled in accordance with the guidelines of the Institutional
Animal Care and Use Committee (Rappaport Faculty of
Medicine, Technion, Haifa, Israel). Rats were housed
individually in stainless steel cages and were acclima-
tized to standard conditions of room temperature (25°C)
with alternating 12-hour light–dark cycles and fed stand-
ard rat chow and water ad libitum during a minimum
stabilization period of five days.
Experimental design
Rats were randomly assigned to one of four experimen-
tal groups: Control (CONTR) rats underwent laparotomy,
isolation of jejunal loop and intraluminal injection of
normal saline. Control-glutamine (CONTR-GLN) rats were
treated with enteral GLN given in drinking water (2%)
48 hours before and 5 days following laparotomy. Control-
acetic acid (C-AA) rats underwent laparotomy, isola-
tion of jejunal loop and intraluminal injection of 2 ml
(0.67 mol/L) AA as previously described [2]. Finally,
acetic acid-glutamine (AA-GLN) rats underwent AA-
induced injury (similarly to C-AA rats) and were treatedwith enteral glutamine 48 hours before and 5 days follow-
ing operation (similarly to C-GLN rats).
Surgical procedure
The rats were preoperatively fasted for 12 hours. Opera-
tive procedures were performed using standard sterile
technique under general anesthesia with ketamine (intra-
peritoneally, 90 mg/kg) and xylazine (intraperitoneally,
10 mg/kg). The abdomen was accessed through a mid-
line incision. C rats underwent laparotomy, isolation of
jejunal loop and intraluminal injection of normal saline.
In AA rats, after laparotomy and isolation of jejunal loop,
atraumatic vascular clamps were used to occlude the iso-
lated intestinal loop, and 2 ml of AA (0.67 mol/L) was
injected into the lumen for 10 minutes. During the period
of injury the abdominal wall incision was kept approxi-
mated to prevent fluid and heat loss. After a 10-minute
period of damage, AA was evacuated and the intestinal
occlusions were released. The intestines were carefully
replaced in the abdomen, and the incision was covered
with moist gauze. The rats were placed on a heating
blanket for the duration of the procedure. They were
subsequently resuscitated with a 3 ml intraperitoneal
injection of warm 0.9% saline, and the incision was closed
with a Dexon S Polyglycolic Acid 3–0 (TYCO Healthcare,
Mansfield, MA) running suture. The rats were then allowed
to awake with free access to water and food.
In the pilot study, changes on days one, three, and five
were investigated after AA injection. Since the histo-
pathological intestinal changes after one and three days
represented mainly acute injury, findings at five days were
regarded as representative of the chronic damage which
resembles inflammatory bowel disease in humans more
accurately. Time of sacrifice was therefore established
at five days after intestinal damage. The rats were re-
anesthetized with intraperitoneal pentobarbital (75 mg/kg)
and were sacrificed by open pneumothorax. Two intes-
tinal segments (proximal jejunum and distal ileum; 10 cm
each) were removed and flushed with cold saline before
recording wet weight. The mucosa was scraped from the
underlying tissue with a glass slide and weighed. Bowel
and mucosal weights were calculated as mg/cm-bowel-
length/100 g-body-weight.
Histological examination
Histological sections were prepared from the proximal
jejunum and distal ileum. Segments of small bowel were
fixed for 24 hours in 4% buffered formalin, cleared in
xylene, and processed into standard paraffin blocks.
Five-micron tissue slices were deparaffinized and were
stained with H&E. The degree of intestinal tissue injury
was evaluated on a grading scale from 0 to 8 as de-
scribed previously by Park et al. [6]: 0 - normal mucosa,

























Figure 1 Effect of acetic acid intestinal injury and glutamine
supplementation on body weight changes. Values are mean ± SEM.
CONTR-control; AA- acetic acid; GLN- glutamine. * P < 0.05 vs CONTR
rats, † P < 0.05 AA-GLN vs AA rats.
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4 - denuded villi, 5 - loss of villus tissue, 6 - crypt layer
infarction, 7 - transmucosal infarction, 8 - transmural
infarction.
Villus height and crypt depth were measured in ten villi
and crypts, using the Image-Pro Plus 4 image analysis
software (Media Cybernetics, Baltimore, Maryland, USA).
Enterocyte proliferation
To determine enterocyte proliferation, rats were in-
jected with standard 5-bromodeoxyuridine (5-BrdU)
labeling reagent (Zymed Laboratories Inc. CA) at a dose
of 1 ml per 100 g body weight 90 minutes before sacri-
fice. Five-micrometer paraffin-embedded slices (5 μm)
were deparaffinized with xylene, rehydrated with graded
alcohol, and stained with a biotinylated monoclonal anti-
BrdU antibody system using the BrdU Staining Kit (Zymed
Laboratories Inc. CA). The proliferation index was defined
as the ratio of crypt cells staining positively for BrdU per
ten crypts.
Enterocyte apoptosis
Apoptotic cells were identified using immunohistochemi-
cal analysis for caspase-3. Caspase-3 (CPP32/YAMA) is a
marker for the early apoptotic phase. Five-micrometer
paraffin-embedded sections were dewaxed and rehydrated
with xylene and graded alcohol. Tissue sections were
microwave-pretreated in 10 mM citrate buffer (pH 6.0).
Immunohistochemical analysis for caspase-3 was per-
formed using the streptavidin-biotin-peroxidase method
according to manufacturer protocols. After the blocking
of endogenous biotin activity, tissue sections were incu-
bated with primary antibodies (Caspase-3 cleaved concen-
trated polyclonal antibody; dilution 1:100; Biocare Medical,
Walnut Creek, CA) for 1 hour at room temperature,
followed by incubation with secondary antibodies (human-
absorbed, biotinylated, affinity-purified antibody) for
20 minutes. The DAB was used to create an intense
brown deposit around the antigen-antibody-enzyme com-
plex in the sample. For each group, the number of stained
cells was counted in two bowel cross sections. The apoptotic
index (AI) was defined as the number of apoptotic cells per
ten villi. Control kit from Eurogentec, EGT Group.
Western blotting
Tissue was homogenized in RIPA lysis buffer containing
50 mM Tris–HCl (pH 7.4), 150 mM NaCl, 1% NP-40,
2 mM EDTA, supplemented with a cocktail of protease
and phosphatase inhibitors. Protein concentrations were
determined by Bradford reagent according to the manu-
facturer’s instructions. Samples containing equal amounts
of total protein (30 μg) were resolved by SDS-PAGE under
reducing conditions. After electrophoresis, proteins were
transferred to a PVDF membrane and probed with variousprimary antibodies to anti-bax antibody (1:200 dilution,
sc-493), anti-phospho-ERK antibody (1:2500 dilution,
sc-7383), and anti-β-Tubulin (1:5000 dilution, Sigma
T6557) was used for the protein normalization. Horse-
radish peroxidase-conjugated secondary antibody was
purchased from Jackson ImmunoResearch Laboratories
Inc. (West Grove, PA) and an enhanced chemilumines-
cent substrate from Biological Industries (Kibbutz Beth
HaEmek, Israel). The optical density of the specific protein
bands was quantified by using a densitometer (Vilber
Lourmat, Lion, France).
Statistical analysis
The data are expressed as the mean ± SEM. A paired
Student’s t-test and the non-parametric Kruskal-Wallis




Treatment of sham rats with enteral GLN (CONTR-GLN
group) did not significantly change final body weight com-
pared to CONTR rats (Figure 1). AA rats demonstrated
a significant decrease in final body weight (97 ± 2 vs.
103 ± 1% initial, p < 0.05) compared to CONTR rats.
Enteral GLN supplementation (AA-GLN group) resulted
in a trend toward increase in final body weight compared
to AA animals; however, this trend did not achieve statis-
tical significance.
Intestinal injury score
Whereas the jejunum and the ileum of CONTR and
CONTR-GLN rats exhibited normal mucosal architec-
ture with intact villi, AA animals exhibited a significant
histologic injury in damaged jejunum and less significant
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cells accumulation, edema and hemorrhage that seen
mainly at site of the injury. AA rats (Group C) demon-
strated a significant increase in the mean intestinal in-
jury grade in jejunum (three-fold, p < 0.05) and ileum
(six-fold, p < 0.05) compared to CONTR rats. Pre-treatment
with oral GLN prevented intestinal mucosal injury caused
by AA. AA-GLN rats attracted significantly lower histo-
logical scores in jejunum (four-fold decrease, p < 0.05) and
ileum (three-fold, p < 0.05) compared to AA rats. How-
ever, AA-GLN rats demonstrated a less effects on inflam-
matory cells accumulation, edema and hemorrhage at site
of the injury.Intestinal mucosal parameters
Treatment of control animals with enteral glutamine
(CONTR-GLN group) did not significantly change bowel
and mucosal weight compared to control animals (C group).
5 days after intestinal damage, there was a decrease in intes-
tinal wall thickness and gut diameter. AA rats had a sig-
nificantly lower bowel weight in ileum (44 ± 7 vs. 54 ± 2,
p < 0.05) and mucosal weight in both jejunum (23 ± 4 vs.
28 ± 1, p < 0.05) and ileum (9 ± 3 vs. 22 ± 1, p < 0.05)
compared to control animals (C group) (Figure 3). AA-
GLN rats demonstrated a trend toward increase in ileal


















Figure 2 Effect of acetic acid and glutamine on the microscopic intes
histologic architecture. AA rats show extended subepithelial space and epi
less marked subepithelial space at villus tip (Park score 1–2). Values are mean
CONTR rats, † P < 0.05 AA-GLN vs AA rats.Microscopic mucosal parameters
AA-rats demonstrated a significant decrease in jejunal
(279 ± 52 vs. 421 ± 37 μm, p < 0.05) and ileal (272 ± 28 vs.
361 ± 39 μm, p < 0.05, p < 0.05) villus height as well as in
jejunal (95 ± 17 vs. 155 ± 14 μm, p < 0.05, p < 0.05) and
ileal (98 ± 20 vs. 175 ± 22 μm, p < 0.05, p < 0.05) crypt
depth compared to CONTR rats (Figure 4). Oral glu-
tamine supplementation (AA-GLN group) caused a sig-
nificant increase in ileal villus height (356 ± 28 vs. 272 ±
28 μm, p < 0.05 p < 0.05) and crypt depth (177 ± 12 vs.
98 ± 20 μm, p < 0.05) as well as a trend toward increase
in jejunal villus height and crypt depth; however, this
trend was not statistically significant.
Enterocyte proliferation and apoptosis
Treatment of control rats with glutamine (CONTR-GLN
group) led to a mild increase in cell proliferation rates in
ileum (165 ± 3 vs. 141 ± 10 BrdU positive cells/10 crypts,
p < 0.05) compared to CONTR rats as well as in a trend
toward increase in cell proliferation rates in jejunum;
however, this trend was not statistically significant
(Figure 5). AA-induced intestinal damage (C-AA rats)
resulted in a significant decrease in the enterocyte prolifera-
tion index in jejunum (98 ± 10 vs. 136 ± 11 BrdU positive
cells/10 crypts, p < 0.05) and ileum (130 ± 12 vs. 141 ±
10 BrdU positive cells/10 crypts, p < 0.05) compared to
control animals. Oral glutamine administration (AA-GLN










tinal appearance. As expected, control rats demonstrate a normal
thelial lifting along villus sides (Park score 3–4). AA-GLN rats exhibited a



































Figure 3 Effect of enteral glutamine on macroscopic intestinal appearance during acetic acid-induced intestinal damage. Values are
mean ± SEM. CONTR-control; AA- acetic acid; GLN- glutamine. * P < 0.05 vs CONTR rats, † P < 0.05 AA-GLN vs AA rats.
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crypts, p < 0.05) compared to AA rats. Both AA and AA-
GLN rats demonstrated a lower cell proliferation rates
compared to CONTR-GLN rats.
CONTR-GLN rats showed a significant increase in cell
apoptosis in jejunum (2.4 ± 0.7 vs. 1.1 ± 0.2 Caspase-3
positive cells/10 villi, p < 0.05) compared to CONTR rats
(Figure 6). AA-induced intestinal damage (Group C)
resulted in a significantly greater number of Caspase-3
positive cells appearing in the villi of jejunum (4.2 ± 0.3
vs 2.8 ± 0.6 apoptotic cells/10 villi, p < 0.05) and ileum
(4.3 ± 0.84 vs. 1.7 ± 0.6 apoptotic cells/10 villi, p < 0.05)
compared to control animals (Figure 3). Pre-treatment
with oral glutamine (AA-GLN) resulted in a significant
decrease in apoptotic index in ileum (three-fold decrease,























Figure 4 Effect of enteral glutamine on microscopic intestinal appear
mean ± SEM. CONTR-control; AA- acetic acid; GLN- glutamine. * P < 0.05 vstoward decrease in cell apoptosis rates in jejunum; how-
ever, this trend was not statistically significant.
Western blotting
Decreased cell proliferation rates in AA animals (Groups
B and C) were accompanied by decreased levels of p-ERK
protein. Interestingly, an increased cell apoptosis was
accompanied by decreased bax-protein levels in AA ani-
mals (Groups B and C) compared to control animals.
Treatment with glutamine (Group C) did not change
significantly the levels of p-ERK and Bax protein com-
pared to AA-nontreated animals (Group B) (Figure 7).
Discussion
The inflammatory bowel diseases, including Crohn’s disease








ance during acetic acid-induced intestinal damage. Values are




































Figure 5 Effect of acetic acid and oral glutamine on crypt cell proliferation. 5-BrdU incorporation into proliferating jejunal and ileal crypt
cells was detected with a goat anti-BrdU antibody. The representative sections (on the right side) demonstrate that cell proliferation decreased
following AA-damage compared to control animals. Following administration of oral glutamine, AA-rats demonstrated a marked increase in a
number of proliferating cells compared to AA non-treated animals. Values are mean ± SEM. CONTR-control; AA- acetic acid; GLN- glutamine.
* P < 0.05 vs CONTR rats, † P < 0.05 AA-GLN vs AA rats.
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activation of the intestinal mucosal immune system [7].
Patients with CD suffer the consequences of a transmural
inflammatory process (classically apparent as “skip lesions”)
and are thus at risk of developing fistulae, whereas colonic
inflammation in UC is continuous, extending from the
rectum proximally. Different animal models of colitis
and colitis-associated cancer have proven in selected
circumstances to be relevant to the pathogenesis of
these disorders in humans. Two of the most widely
used non-genetic colitis models are the dextran sodium
sulfate (DSS)-induced chemical injury model, and the
trinitrobenzene sulfonic acid (TNBS) hapten-induced
model [8-10]. DSS in drinking water induces an acute
colitis within 5 days of exposure, and can also be uti-
lized to mimic chronic colitis following repeated exposure
[10,11]. TNBS is administered by enema and results in a
hapten-induced, interleukin-12 (IL-12) driven colitis [12].
As summarized in Rosenstiel et al. [13], some mouse
models correlate well with human disease risk loci or
associated pathways, whereas others do not yet have
clear relevance to human clinical syndromes.
We recently developed a novel rodent model system
to study AA-induced small intestinal injury, by adminis-
tering AA (0.67 mol/L) directly to a ligated intestinal
loop of anesthetized rats that may be relevant to the
pathogenesis of small intestinal chronic inflammationlike Crohn’s disease in humans. In the pilot study one,
three and five-day changes were investigated after AA
injection. After one and three days, the histopatho-
logical changes in the intestine represented mainly acute
injury, whereas after five days we observed the signs
of chronic damage that resemble human inflammatory
bowel disease more accurately. Therefore, five days after
intestinal damage was chosen as the time of sacrifice. In
the current study, the effects of dietary GLN supple-
mentation on structural mucosal changes following AA-
induced intestinal injury were evaluated. There is a growing
body of evidence to suggest that various nutrients may
improve mucosal recovery after gut damage. GLN is a
non-essential amino acid, which is produced mainly by
the muscle, and which plays an important role in many
physiological and biological processes. GLN is the pri-
mary metabolic fuel of the small amino acid pool in the
body, and has been shown to be an essential metabolic
component of the proliferative response of enterocytes.
While in the large bowel the short chain fatty acid bu-
tyrate is the preferred fuel, several experimental studies
have indicated that GLN is one of the preferred fuel
sources for the small intestine [14]. Extensive studies in
various experimental models have established the posi-
tive effect of GLN on the small intestinal mucosa fol-
lowing intestinal damage [15-20]. However, studies on





























Figure 6 Effect of acetic acid and oral glutamine on enterocyte apoptosis. Immunohistochemistry for caspase-3 was used to determine
enterocyte apoptosis. The representative sections (on the right side) demonstrate that the number of the Caspase-3 positive cells increased
significantly following AA compared to control animals and decreased significantly after treatment with glutamine. Values are mean ± SEM.
CONTR-control; AA- acetic acid; GLN- glutamine. * P < 0.05 vs CONTR rats, † P < 0.05 AA-GLN vs AA rats.
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few and controversial. GLN might stimulate mucosal
recovery via direct stimulation of proliferation or cell
migration, or via inhibition of enterocyte apoptosis.
Alternatively, it might exert its pro-adaptive effect by
stimulating the release of various trophic agents or by
altering absorption and secretion of nutrients. In a re-
cent review, Mok et al. provide a critical appraisal of
the literature on gutamine supplementation in various
conditions or illnesses that affect children, from neonates
to adolescents, including inflammatory bowel disease [21].
They state that whereas animal models of IBD have indi-
cated potentially beneficial effects of supplemental GLN,
clinical studies of GLN in inflammatory bowel disease
have been less encouraging. The initial trial found no
evidence that GLN enriched polymeric diet is of any
benefit over standard polymeric diet in the treatment of
children with active Crohn’s disease as well as there
were no differences in remission rates, changes in plate-
let count, orosomucoid level, or weight.
In the present study, we evaluated the consequences
of oral GLN in preventing mucosal injury by AA and ongut recovery following injury. Alterations in bowel and
mucosal weights, as well as histological appearance were
evaluated. Intestinal mucosal parameters were calculated
per cm of bowel weight. BrdU was used in our experi-
ment to determine an index of crypt cell proliferation.
This analogue of thymidine is incorporated into the DNA
of proliferating cells during the S-phase of the cell cycle.
Immunohistochemistry for caspase-3 was used to charac-
terize enterocyte apoptosis. Our data demonstrated that
injection of AA produced severe small intestinal dam-
age, an effect which was most prominent in the isolated
proximal segment but which was almost absent in the
distal ileum. This is evident from the increased Park
intestinal injury score, observed in both jejunum and
ileum; however, the damaging effect was more significant
in the jejunum. The intestinal injury in this group was
intermediate (Grade 4 in jejunum and grade 2 or 3 in
ileum), with no single animal showing very severe tissue
damage. Additionally, intestinal damage led to intestinal
mucosal hypoplasia, apparent as decreased bowel and mu-
cosal weight. A trend toward increase in bowel weight in



























Figure 7 Effect of acetic acid and oral glutamine on expression
of p-ERK, and bax protein (Western blot) in intestinal mucosal
samples. Values are mean ± SEM. CONTR-control; AA- acetic acid;
GLN- glutamine. * P < 0.05 vs CONTR rats, † P < 0.05 AA-GLN vs AA rats.
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vascular engorgement rather than mucosal hyperplasia.
Our data show that enterocyte proliferation was down-
regulated while cell death via apoptosis increased sig-
nificantly in both jejunum and ileum during intestinal
damage. A decreased rates of cell proliferation were
accompanied by increased p-ERK protein levels. The extra-
cellular signal-related kinase (ERK) is one of the MAPK
signaling pathways triggered by cytokines or growth
factors and regulates various cellular activities, such as
gene expression, mitosis, cell proliferation, differenti-
ation and apoptosis. A more significant increase in cell
death was observed in the proximal jejunum (area of
damage). Less significant damage to the distal ileum may
be due to a lower achievable concentration of AA in distal
segments. Our data also demonstrated that programmed
cell death is one of the pathways leading to mucosal
damage, in consistence with data from previous studies
[22-24]. Interestingly, the expression of pro-apoptotic
Bax protein was down-regulated in AA rats compared
to sham animals despite the increased rates of cell apop-
tosis. We believe that the decreased Bax expression cre-
ates a higher resistance of enterocytes to apoptosis. The
other explanation of this phenomenon may be the differ-
ent rates of apoptosis at multiple time points following
intestinal damage. Consistent with this concept, is thefact that in the first 2–3 days after injury the stimuli for
adaptation may suppress programmed cell death in an
attempt to increase the cell mass. At this time point
down-regulation of the Bax protein may drive decreased
cell apoptosis. Five days after bowel damage, when the
bulk of immature enterocyte appears, cell apoptosis in-
creases significantly in order to reach a new homeostatic
point during intestinal adaptation, in order to promote
disposal of genetically aberrant stem cells and to prevent
tumorogenesis. At this time point, down-regulation of Bax
mRNA coincides with decreased number of Caspase-3
positive cells. These findings suggest an important role for
the differential regulation of apoptosis related genes as
coordinators of the early increase in cell apoptosis after
intestinal damage. Both reduced cell proliferation and
enhanced cell apoptosis in the current study indicate re-
duced enterocyte turnover, which could explain mucosal
hypoplasia after AA-induced damage.
In this study, GLN treatment had a beneficial effect in
preventing intestinal damage. Administration of oral GLN
ameliorated AA-associated tissue damage. Intestine from
GLN-treated rats exhibited reversal of villus epithelium
loss and injury, as well as a decrease in Park injury score.
In addition, AA-induced mucosal hypoplasia was partly
ameliorated by oral GLN administration. This was evident
as increased bowel and mucosal weight, which is charac-
teristic of tissues undergoing increased cell proliferation
or repair. Histologically, villus height and crypt depth
increased in response to GLN administration, suggesting
increased absorptive surface area. Preserved cell viability
following treatment with glutamine leads to enhanced en-
terocyte turnover and improves gut recovery. The strong
increase in the proliferation of crypt cells in the intestinal
mucosa of glutamine treated rats seen here is of much
significance and correlates with the crypt depth observed.
The number of caspase-3-positive cells decreased signifi-
cantly following GLN administration, suggesting that GLN
exerts its positive effect on intestinal recovery through both
stimulation of proliferation and inhibition of apoptosis.
The positive effect of GLN on non-stressed intestinal
mucosa including its stimulating effect on enterocyte
proliferation has been extensively described in various
experimental studies; however, the molecular mecha-
nisms whereby it enhances intestinal cell growth have
not been clearly elucidated. GLN was found to prevent
5-fluorouracil-induced apoptosis and necrosis in an un-
differentiated crypt intestinal cell lines [25]. Our find-
ings demonstrate that treatment with glutamine appears
to be considerably less effective in activating the MAPK
pathway. Further experiment are required to determine
whether other pathways (Like PI3K/Akt signaling) may
be responsible in transducing increased cell proliferating
activity following GLN administration. A recent study has
demonstrated that activation protein kinase D (PKD) and
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contributor to GLN-mediated intestinal cell survival [26].
Finally, the present study demonstrates that oral GLN
attenuates intestinal mucosal injury and accelerates in-
testinal recovery following AA-induced intestinal dam-
age in rats. This benefit correlates with an increase in
enterocyte proliferation and decreased cell apoptosis in
intestinal mucosa.
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